These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 6769585)

  • 1. A sensitive and specific assay for pentamethylmelamine in plasma: applicability to clinical studies.
    Dutcher JS; Jones RB; Boyd MR
    Cancer Treat Rep; 1980 Jan; 64(1):99-104. PubMed ID: 6769585
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I trial of pentamethylmelamine: a clinical and pharmacologic study.
    Ihde DC; Dutcher JS; Young RC; Cordes RS; Barlock AL; Hubbard SM; Jones RB; Boyd MR
    Cancer Treat Rep; 1981; 65(9-10):755-62. PubMed ID: 6791819
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I and pharmacological studies of pentamethylmelamine administered by 24-hour intravenous infusion.
    Casper ES; Gralla RJ; Lynch GR; Jones BR; Woodcock TM; Gordon C; Kelsen DP; Young CW
    Cancer Res; 1981 Apr; 41(4):1402-6. PubMed ID: 6783296
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of hexamethylmelamine and pentamethylmelamine in mice.
    Broggini M; Colombo T; D'Incalci M; Donnelli MG; Gescher A; Garattini S
    Cancer Treat Rep; 1981; 65(7-8):669-72. PubMed ID: 6788370
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disposition and metabolism of pentamethylmelamine and hexamethylmelamine in rabbits and humans.
    Ames MM; Powis G; Kovach JS; Eagan RT
    Cancer Res; 1979 Dec; 39(12):5016-21. PubMed ID: 115586
    [TBL] [Abstract][Full Text] [Related]  

  • 6. First-pass metabolism of pentamethylmelamine in the rat liver.
    Klippert PJ; Hulshoff A; Hofman GA; Noordhoek J
    Cancer Res; 1985 Mar; 45(3):983-6. PubMed ID: 3918792
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Variable oral absorption of hexamethylmelamine in man.
    D'Incalci M; Bolis G; Mangioni C; Morasca L; Garattini S
    Cancer Treat Rep; 1978 Dec; 62(12):2117-9. PubMed ID: 109196
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Specific determination of pentamethylmelamine and its demethylated metabolites in human plasma by high pressure liquid chromatography.
    Leyland-Jones BR; Deesen PE; Casper ES; Young CW
    Ther Drug Monit; 1982; 4(2):185-90. PubMed ID: 6808715
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I trial of pentamethylmelamine in patients with previously treated malignancies.
    Van Echo DA; Chiuten DF; Whitacre M; Aisner J; Lichtenfeld JL; Wiernik PH
    Cancer Treat Rep; 1980; 64(12):1335-9. PubMed ID: 6781747
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hexamethylmelamine and pentamethylmelamine tissue distribution in M5076/73A ovarian cancer-bearing mice.
    Broggini M; Rossi C; Colombo T; D'Incalci M
    Cancer Treat Rep; 1982 Jan; 66(1):127-33. PubMed ID: 6796267
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early clinical trial of a 1-day intermittent schedule for pentamethylmelamine.
    Eagan RT; Creagan ET; Rubin J; O'Connell MJ; Kovach JS
    Cancer Treat Rep; 1980; 64(8-9):993-5. PubMed ID: 6778613
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pentamethylmelamine (PMM): Phase I clinical and pharmacokinetic studies.
    Muindi JR; Newell DR; Smith IE; Harrap KR
    Br J Cancer; 1983 Jan; 47(1):27-33. PubMed ID: 6401427
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacology of pentamethylmelamine in humans.
    Benvenuto JA; Stewart DJ; Benjamin RS; Loo TL
    Cancer Res; 1981 Feb; 41(2):566-9. PubMed ID: 6778609
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Application of liquid chromatography-mass spectrometry to monitoring plasma cyclophosphamide levels in phase I trial cancer patients.
    Liu JJ; Kestell P; Findlay M; Riley G; Ackland S; Simpson A; Isaacs R; McKeage MJ
    Clin Exp Pharmacol Physiol; 2004 Oct; 31(10):677-82. PubMed ID: 15554907
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Determination of pentamethylmelamine and hexamethylmelamine in plasma and urine by nitrogen-phosphorus gas-liquid chromatography.
    Ames MM; Powis G
    J Chromatogr; 1979 Jun; 174(1):245-9. PubMed ID: 121123
    [No Abstract]   [Full Text] [Related]  

  • 16. Dose-dependent pharmacokinetics of PMM in the rat.
    Colombo T; Torti L; D'Incalci M
    Cancer Chemother Pharmacol; 1981; 5(3):201-3. PubMed ID: 6794923
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The comparative pharmacokinetics of pentamethylmelamine in man, rat, and mouse.
    Rutty CJ; Newell DR; Muindi JR; Harrap KR
    Cancer Chemother Pharmacol; 1982; 8(1):105-11. PubMed ID: 6807560
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development and validation of a liquid chromatography-mass spectrometry (LC-MS) assay for the determination of the anti-cancer agent N-[2-(dimethylamino)ethyl]-2,6-dimethyl-1-oxo-1,2-dihydrobenzo[b]-1,6-naphthyridine-4-carboxamide (SN 28049).
    Lukka PB; Kestell P; Paxton JW; Baguley BC
    J Chromatogr B Analyt Technol Biomed Life Sci; 2008 Nov; 875(2):368-72. PubMed ID: 18926778
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NTP technical report on the toxicity and metabolism studies of chloral hydrate (CAS No. 302-17-0). Administered by gavage to F344/N rats and B6C3F1 mice.
    Beland FA
    Toxic Rep Ser; 1999 Aug; (59):1-66, A1-E7. PubMed ID: 11803702
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human central nervous system pharmacology of pentamethylmelamine and its metabolites.
    Stewart DJ; Benvenuto JA; Leavens M; Smith RG; Cabanillas F; Benjamin RS; Loo TL
    J Neurooncol; 1983; 1(4):357-64. PubMed ID: 6432969
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.